Percent increase in weight for rats with endometriosis treated with antalarmin or vehicle.

Annelyn Torres-Reverón (5650028), Leslie L. Rivera-Lopez (5963024), Idhaliz Flores (5650034), Caroline B. Appleyard (5650037)
2018 · doi:10.1371/journal.pone.0197698.g010 · W6941863325
Lab / animal OA: green CC0
🔓 Open OA copy Full text JSON View on OpenAlex View at publisher
⚙ AI-generated deep summary by qwen3.7-flash, 2026-09-11 · read from full text ⓘ

This study investigated the effect of antalarmin, a corticotropin-releasing hormone receptor 1 antagonist, on the progression of endometriosis in a rat model. The researchers measured the percent increase in weight of endometriotic lesions following treatment with either antalarmin or a vehicle control over several weeks. Results indicated that antalarmin significantly reduced lesion weight compared to controls, with differences persisting for two days after treatment cessation and reaching statistical significance by weeks six and seven. This paper is centrally about endometriosis — specifically evaluating the therapeutic potential of CRHR1 antagonism in reducing lesion burden in an experimental animal model.

Read from the paper's body, not the abstract. Not a substitute for reading the paper. No clinical advice. How this works

Abstract

(A) After seven days of treatment, antalarmin treatment significantly decreased the weight of the rats and this difference persisted for two additional days after the drug treatment has stopped. (B) During the subsequent weeks, the antalarmin group remained weighing less than control group and by weeks 6 and 7 this difference reached statistical significance. * p< 0.05, ** p< 0.01.
Full text 599 characters · extracted from oa-doi-fallback · click to expand
Antagonizing the corticotropin releasing hormone receptor 1 with antalarmin reduces the progression of endometriosis Fig 10 Percent increase in weight for rats with endometriosis treated with antalarmin or vehicle. (A) After seven days of treatment, antalarmin treatment significantly decreased the weight of the rats and this difference persisted for two additional days after the drug treatment has stopped. (B) During the subsequent weeks, the antalarmin group remained weighing less than control group and by weeks 6 and 7 this difference reached statistical significance. * p< 0.05, ** p< 0.01.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosis

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

openalex
last seen: 2026-05-11T08:49:27.301386+00:00
License: CC0 · commercial use OK